One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer?
doi : 10.1200/JCO-24-02514
2025, Volume 43 (6)
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years
doi : 10.1200/JCO-24-01676
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials
doi : 10.1200/JCO-24-01579
Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
doi : 10.1200/JCO.24.01146
Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer
doi : 10.1200/JCO.24.00965
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial
doi : 10.1200/JCO.24.00681
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice
doi : 10.1200/JCO.23.02761
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
doi : 10.1200/JCO.24.00259
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
doi : 10.1200/JCO.24.00511
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
doi : 10.1200/JCO.24.01034
Second MEK Inhibitor Shows Promise in Neurofibromatosis Type 1 With Symptomatic Plexiform Neurofibromas Signaling Hope for Other RASopathies
doi : 10.1200/JCO-24-02375
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
doi : 10.1200/JCO-24-01534
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
doi : 10.1200/JCO-24-02608
Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies
doi : 10.1200/JCO-24-01869
Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies
doi : 10.1200/JCO-24-02388
Significance of Up-Front Stereotactic Radiosurgery for Non–Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors
doi : 10.1200/JCO-24-01876
Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non–Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors
doi : 10.1200/JCO-24-02129
Comment on the Definition and Interpretation of Complete Mesocolic Excision in the RELARC Trial
doi : 10.1200/JCO-24-02228
Reply to: Comment on the Definition and Interpretation of Complete Mesocolic Excision in the RELARC Trial
doi : 10.1200/JCO-24-02307
